13 December 2016 - The Biosafety Council issues a positive advice (with conditions) for this trial
EU record number
B/BE/16/BVW1
EudraCT number
2014-005386-67
Company / Sponsor
Amgen Ltd
Treated organism
Humans
Indication category
Treatment of hepatocellular carcinoma (HCC) and metastatic liver tumors (non-HCC)
Genetic modification
Insertion of a gene expressing granulocyte-macrophage colony-stimulating factor (hGM-CSF) - Functional deletion of two genes (ICP34.5 and ICP47) of the HSV-1 genome
Method of transfer of nucleic acid of interest
Herpes simplex virus 1 (HSV-1)
Route of administration
Intrahepatic injection
Locations in Belgium
UCL Cliniques Universitaires Saint Luc (Bruxelles), Universitair Ziekenhuis Gent, Universitair Ziekenhuis Leuven Campus Gasthuisberg, Universitair Ziekenhuis Antwerpen
Foreseen duration
April 2017 to December 2019